Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Israeli bio-pharmaceutical Kamada has begun human phase I trials of an inhaled formulation of its drug, alpha 1-proteinase inhibitor (API), for congenital emphysema.
Subscribe to our email newsletter
The trials will examine the product’s safety according to a plan approved by the European Agency for Evaluation of Medicinal Products.
Kamada has also signed a strategic agreement with Pari, a Germany-based leader in aerosol therapies, for the conjoint clinical development and marketing of API administered by inhalation.
Under the agreement, Pari grants Kamada the exclusive license to use Pari’s eFlow Electronic Nebulizer for clinical trials and to commercialize Kamada’s API with the eFlow device.
“The respiratory form of API also represents a revolution in treatment as it provides the patient with a much higher level of comfort. It also has considerable financial advantages since a much lower dose is required compared to the infused version, enabling the treatment of a greater number of patients,” said David Tsur CEO of Kamada.
Kamada’s API holds orphan drug designation for the treatment of congenital emphysema and cystic fibrosis in Europe and the US.